Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

Recent & Breaking News (TSX:MSCL)

Satellos Bioscience Inc. Announces Pricing of Proposed Offering of Units

Newsfile August 30, 2022

Satellos Bioscience Inc. Announces the Filing of an Amended and Restated Preliminary Prospectus for Proposed Offering of Units

Newsfile August 29, 2022

Satellos Bioscience Reports Q2 2022 Financials and Operating Results

Newsfile August 29, 2022

Satellos Bioscience (TSXV:MSCL) awarded grant from the Canadian Institutes of Health Research

Sabrina Cuthbert July 25, 2022

Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Awarded Significant Grant from the Canadian Institutes of Health Research

Newsfile July 25, 2022

Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature Communications

Newsfile July 13, 2022

Satellos Bioscience Inc. Announces Proposed Offering of Units

Newsfile July 11, 2022

Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Brieanna McCutcheon  June 30, 2022

Satellos Bioscience Announces In-Licensing of New Patent Application

Newsfile June 29, 2022

Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society

Newsfile June 22, 2022

Satellos' (TSXV:MSCL) co-founder receives prestigious grant award

Shoran Devi June 17, 2022

Satellos Bioscience Co-Founder and Chief Scientific Officer Awarded Prestigious Defeat Duchenne Canada 2022 Grant

Newsfile June 17, 2022

Satellos Bioscience Inc. to Present at Bio International Convention 2022

Newsfile June 14, 2022

Satellos Bioscience to Present at the LD Micro Invitational

Newsfile June 1, 2022

Satellos Bioscience Inc. Announces First Quarter Financial Results and Operational Highlights

Newsfile May 31, 2022

Satellos Bioscience Announces 2021 Year End Financial Results and Operational Highlights

Newsfile April 29, 2022

Satellos Bioscience Inc. Invited to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Newsfile April 26, 2022

Satellos Bioscience Inc. to Present Game Changing Science at Upcoming European Molecular Biology Organization Workshop

Newsfile April 21, 2022

Satellos Bioscience Inc.'s CSO to Present Game Changing Science During March 30th Drug Discovery News Webinar

Newsfile March 29, 2022

Satellos Bioscience Provides Update on Novel Regenerative Drug Candidates

Newsfile March 15, 2022